HTLV-1 and ATL: Decoding Molecular Pathogenesis for Next-Generation Therapies

Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-lymphocyte malignancy arising as a late consequence of human T-cell leukemia virus type 1 (HTLV-1) infection. Despite decades of research, ATL remains characterized by a dismal prognosis and high relapse rates, representing a significant clinical challenge. This review proposes a unifying model of ATL pathogenesis centered on the transition from a transient, Tax-driven early transformation to a constitutive, HBZ-mediated persistent state. We present this switch as a unifying conceptual framework, and explicitly distinguish its well-supported components from those that remain mechanistic interpretations, given the substantial heterogeneity of Tax expression and of the mechanisms underlying Tax loss across ATL cases. We describe how this "Tax-to-HBZ switch" orchestrates an integrated molecular circuit where viral plus-strand latency-maintained through coordinated DNA hypermethylation and chromatin remodeling-directly facilitates immune evasion and therapeutic resistance. Critical knowledge gaps are highlighted, particularly the lack of therapeutic strategies capable of targeting the "Tax-off" latent cell reservoir and the mechanisms by which the bone marrow and stromal niches provide sanctuary from treatment-induced apoptosis. Furthermore, we provide a critical appraisal of emerging targeted molecules, immunotherapies, and gene-editing approaches, distinguishing between their preclinical promise and the clinical realities of toxicity and resistance. This integrated perspective aims to provide a roadmap for developing more durable, next-generation therapies for this complex virus-driven malignancy.